Brief: Antengene Receives CDE Endorsement For Phase III Clinch-3 Study Of ATG-22 In China
28/05/2026 02:40
BRIEF-Antengene Receives CDE Endorsement For Phase III Clinch-3 Study Of ATG-22 In China May 28 (Reuters) - Antengene Corp Ltd 6996.HK:
RECEIVES CDE ENDORSEMENT FOR PHASE III CLINCH-3 STUDY OF ATG-22 IN CHINA
Further company coverage: 6996.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Antengene
See all newsBiotech firm Antengene's H1 revenue jumps on licensing deals
Brief: Antengene Corp Expects HY Profit Of RMB195 MLN-RMB238 MLN
Brief: Antengene Corp Receives Initial $60 Million Upfront Payment From UCB
Brief: Antengene Corp Intends To Repurchase Up To 67.92 Million Shares
Brief: Antengene Corp Enters Exclusive License Agreement With K2 Therapeutics For Atg-106